Synthetic Peptide H-473 Multi-Target Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, asthma, senile dementia, psoriasis, and age-related macular degeneration often have limited efficacy and multi-target therapeutic options, with existing drugs having side effects and not fully addressing the complexities of these diseases.
Innovation Solution
An artificially synthesized peptide H-473 with the amino acid sequence RGLRGLR, which interferes with specific receptors and cytokines involved in these diseases, demonstrating significant inhibitory effects on cancer cell growth, asthma symptoms, acetylcholinesterase expression, psoriasis-related protein down-regulation, and vascular proliferation in age-related macular degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used for targeted therapy, then therapeutic effect is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with small molecule peptides (7-10 amino acids) that are cheaper to produce, have shorter half-lives, and can be administered more frequently at lower costs while maintaining therapeutic efficacy through multi-target inhibition
Solution Approach 2:
The patent changes the molecular parameters from large protein structures (monoclonal antibodies) to small peptide molecules (7-10 amino acids), altering pharmacokinetic properties including shorter half-life, smaller molecular weight, and different tissue penetration characteristics to achieve cost-effective therapy
2Device complexity
If single-target drugs are used, then mechanism is simple, but therapeutic efficacy is limited for complex diseases
Solution Approach 1:
The patent designs small molecule peptides with multi-target inhibition capabilities, where a single peptide can simultaneously bind to multiple receptors and cytokines involved in different disease pathways, providing broad-spectrum therapeutic effects for complex diseases like cancer, asthma, and autoimmune disorders
Solution Approach 2:
The patent segments the complex disease pathways into multiple targetable interaction points, using small peptides that can simultaneously interfere with multiple protein-protein interactions in parallel, thereby addressing the complexity of diseases through distributed multi-target inhibition
Data Source
AI summary
The invention discloses an artificially synthesized peptide H-473 and use thereof. The peptide H-473 has an amino acid sequence of RGLRGLR, a molecular weight of 827 Da and a PI of 12.30. The invention further discloses use of the peptide H-473 in anti-cancer, anti-senile dementia, analgesia and the like. The peptide H-473 provides scientific basis and direction for research and development of anti-cancer, anti-asthma, anti-senile dementia and analgesia, provides a valuable resource for studying mechanisms of anti-cancer, anti-asthma, anti-senile dementia, analgesia and anti-psoriasis, and provides a new direction for researching novel means for anti-cancer, anti-asthma, anti-senile dementia, analgesia, anti-psoriasis and anti-age-related macular degeneration (AMD).